Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension.
BACKGROUND
We previously reported the feasibility of an acute, orally delivered, newly developed, conjugated form of human B-type natriuretic peptide (hBNP) in normal animals. The objective of the present study was to extend our findings and to define the chronic actions of an advanced oral conjugated hBNP (hBNP-054) administered for 6 days on sodium excretion and blood pressure. We also sought to establish the ability of this new conjugate to acutely activate cGMP and to reduce blood pressure in an experimental model of angiotensin II (ANG II) -mediated hypertension.


RESULTS
First, we developed additional novel conjugated forms of oral hBNP that were superior to our previously reported hBNP-021 in reducing blood pressure in 6 normal dogs. We then tested the new conjugate, hBNP-054, chronically in 2 normal dogs to assess its biological actions as a blood pressure-lowering agent and as a natriuretic factor. Second, we investigated the effects of acute oral hBNP-054 or vehicle in 6 dogs that received continuous infusion of ANG II to induce hypertension. After baseline determination of mean blood pressure (MAP) and blood collection for plasma hBNP and cGMP, all dogs received continuous ANG II infusion (20 ng . kg(-1) . min(-1), 1 mL/min) for 4 hours. After 30 minutes of ANG II, dogs received oral hBNP-054 (400 microg/kg) or vehicle in a random crossover fashion with a 1-week interval between dosing. Blood sampling and MAP measurements were repeated 30 minutes after ANG II administration and 10, 30, 60, 120, 180, and 240 minutes after oral administration of hBNP-054 or vehicle. In the chronic study in normal dogs, oral hBNP-054 effectively reduced MAP for 6 days and induced a significant increase in 24-hour sodium excretion. hBNP was not present in the plasma at baseline in any dogs, and it was not detected at any time in the vehicle group. However, hBNP was detected throughout the duration of the study after oral hBNP-054, with a peak concentration at 30 minutes of 1060+/-818 pg/mL. In the acute study, after ANG II administration, plasma cGMP was not activated after vehicle, whereas it was significantly increased after oral hBNP-054 (P=0.01 between the 2 groups). Importantly, MAP was significantly increased after ANG II throughout the acute study protocol. However, although no changes occurred in MAP after vehicle administration, oral hBNP-054 reduced MAP for >2 hours (from 138+/-1 mm Hg after ANG II to 124+/-2 mm Hg at 30 minutes, 124+/-2 mm Hg at 1 hour, and 130+/-5 mm Hg at 2 hours after oral hBNP-054; P<0.001).


CONCLUSIONS
This study reports for the first time that a novel conjugated oral hBNP possesses blood pressure-lowering and natriuretic actions over a 6-day period in normal dogs. Furthermore, hBNP-054 activates cGMP and reduces MAP in a model of acute hypertension. These findings advance the concept that orally administered chronic BNP is a potential therapeutic strategy for cardiovascular diseases such as hypertension.
Cataliotti
Alessandro
A
Cardiorenal Research Laboratory, Mayo Clinic and Foundation, Rochester, MN 55905, USA. cataliotti.alessandro@mayo.edu
Chen
Horng H
HH
Schirger
John A
JA
Martin
Fernando L
FL
Boerrigter
Guido
G
Costello-Boerrigter
Lisa C
LC
James
Kenneth D
KD
Polowy
Karen
K
Miller
Mark A
MA
Malkar
Navdeep B
NB
Bailey
Kent R
KR
Burnett
John C
JC
D000284:Administration, Oral; D000595:Amino Acid Sequence; D000804:Angiotensin II / Q000097:blood / Q000633:toxicity*; D000818:Animals; D004285:Dogs; D004334:Drug Administration Schedule; D006973:Hypertension / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008969:Molecular Sequence Data; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000097:blood; D011897:Random Allocation
D000804:Angiotensin II; D020097:Natriuretic Peptide, Brain